256 related articles for article (PubMed ID: 22054892)
1. Gene therapy for lung neoplasms.
Vachani A; Moon E; Wakeam E; Haas AR; Sterman DH; Albelda SM
Clin Chest Med; 2011 Dec; 32(4):865-85. PubMed ID: 22054892
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for mesothelioma and lung cancer.
Vachani A; Moon E; Wakeam E; Albelda SM
Am J Respir Cell Mol Biol; 2010 Apr; 42(4):385-93. PubMed ID: 20160042
[TBL] [Abstract][Full Text] [Related]
3. Mesothelioma: an inviting but challenging target for gene therapy.
Crystal RG
Am J Respir Cell Mol Biol; 2010 Apr; 42(4):383-4. PubMed ID: 20228386
[No Abstract] [Full Text] [Related]
4. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
6. Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
Sterman DH; Alley E; Stevenson JP; Friedberg J; Metzger S; Recio A; Moon EK; Haas AR; Vachani A; Katz SI; Sun J; Heitjan DF; Hwang WT; Litzky L; Yearley JH; Tan KS; Papasavvas E; Kennedy P; Montaner LJ; Cengel KA; Simone CB; Culligan M; Langer CJ; Albelda SM
Clin Cancer Res; 2016 Aug; 22(15):3791-800. PubMed ID: 26968202
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
Ceresoli GL; Bonomi M; Sauta MG
Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
[No Abstract] [Full Text] [Related]
8. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
Fridlender ZG; Sun J; Singhal S; Kapoor V; Cheng G; Suzuki E; Albelda SM
Mol Ther; 2010 Nov; 18(11):1947-59. PubMed ID: 20683443
[TBL] [Abstract][Full Text] [Related]
9. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
Murthy V; Katzman D; Sterman DH
Clin Respir J; 2019 May; 13(5):272-279. PubMed ID: 30810270
[TBL] [Abstract][Full Text] [Related]
10. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for malignant pleural mesothelioma: present and future.
Tada Y; Takiguchi Y; Hiroshima K; Shimada H; Ueyama T; Nakamura M; Tatsumi K; Kuriyama T; Tagawa M
Oncol Res; 2008; 17(6):239-46. PubMed ID: 19192718
[TBL] [Abstract][Full Text] [Related]
12. A potential therapeutic strategy for malignant mesothelioma with gene medicine.
Tada Y; Shimada H; Hiroshima K; Tagawa M
Biomed Res Int; 2013; 2013():572609. PubMed ID: 23484132
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
Calabrò L; Ceresoli GL; D'Incecco A; Scherpereel A; Aerts J; Maio M
Cytokine Growth Factor Rev; 2017 Aug; 36():25-31. PubMed ID: 28736182
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
16. Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.
Suzawa K; Shien K; Peng H; Sakaguchi M; Watanabe M; Hashida S; Maki Y; Yamamoto H; Tomida S; Soh J; Asano H; Tsukuda K; Nasu Y; Kumon H; Miyoshi S; Toyooka S
Anticancer Res; 2017 Jan; 37(1):301-307. PubMed ID: 28011506
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
Lee HS; Jang HJ; Choi JM; Zhang J; de Rosen VL; Wheeler TM; Lee JS; Tu T; Jindra PT; Kerman RH; Jung SY; Kheradmand F; Sugarbaker DJ; Burt BM
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618661
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for malignant pleural mesothelioma.
Sterman DH; Kaiser LR; Albelda SM
Hematol Oncol Clin North Am; 1998 Jun; 12(3):553-68. PubMed ID: 9684098
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
20. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
